Incyte | INCY - Trade Creditors


Incyte reported $1.63B in Trade Creditors for its fiscal quarter ending in December of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 10.9M 10.84M Dec/2025
Agenus USD 85.29M 10.89M Sep/2025
Agios Pharmaceuticals USD 18.36M 1.2M Dec/2025
Alnylam Pharmaceuticals USD 115.72M 1.87M Dec/2025
Amgen USD 20.89B 1.25B Dec/2025
BioCryst Pharmaceuticals USD 5.57M 3.02M Sep/2025
Biogen USD 432M 18.9M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Eli Lilly USD 5.38B 1.12B Dec/2025
Exelixis USD 29.62M 4.27M Dec/2025
Gilead Sciences USD 808M 226M Sep/2025
Incyte USD 1.63B 1.46B Dec/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Merck USD 4.15B 102M Sep/2025
Moderna USD 317M 50M Dec/2025
Nektar Therapeutics USD 15.56M 1.28M Sep/2025
Neurocrine Biosciences USD 545.5M 425.6M Dec/2025
Novartis USD 4.56B 49M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
PTC Therapeutics USD 45.49M 8.87M Dec/2025
Puma Biotechnology USD 6.39M 962K Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Sarepta Therapeutics USD 280.84M 186.83M Dec/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 3.43B 600.9M Dec/2025